Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + miniCHP + obinutuzumab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Polatuzumab vedotin + miniCHP + obinutuzumab is a combination chemoimmunotherapy regimen primarily investigated as an induction backbone for the treatment of diffuse large B-cell lymphoma (DLBCL), particularly the MCD subtype. The regimen consists of polatuzumab vedotin, an antibody-drug conjugate (ADC) targeting CD79b that delivers the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE); obinutuzumab, a glycoengineered Type II anti-CD20 monoclonal antibody; and a reduced-dose chemotherapy backbone known as miniCHP, which includes cyclophosphamide, doxorubicin, and prednisone. By omitting vincristine (the 'O' in standard CHOP), the regimen aims to reduce cumulative neurotoxicity while providing potent B-cell depletion through dual targeting of CD79b and CD20. This combination is often evaluated in clinical trials alongside novel targeted therapies, such as BTK inhibitors like orelabrutinib, to improve outcomes in newly diagnosed high-risk lymphoma patients.
- Other names
- Pola-G-miniCHPPola-Obinutuzumab-miniCHPPola-G-CHPvepoliximab + miniCHP + obinutuzumab
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainDNAFcγRIIIa/b (Low affinity immunoglobulin gamma Fc region receptor III-A/B)GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on polatuzumab vedotin + miniCHP + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + miniCHP + obinutuzumab.